FAST NEWS: Drug companies say they’re unaffected by Silicon Valley Bank failure
The latest: Several Hong Kong-listed pharmaceutical companies disclosed that they have deposits at U.S.-based Silicon Valley Bank (SVB), which was taken over by the Federal Deposit Insurance Corp. (FDIC) last…
BGNE.US
6160.HK
Zai Lab sees profits on the horizon as commercialization accelerates
The innovative drug maker’s loss narrowed last year, as it forecast potential profitability as soon as 2025 on fast-growing revenues Key Takeaways: Zai Lab is set to reach several product…
9688.HK
ZLAB.US
FAST NEWS: BeiGene Loss Narrows on Brisk Sales for Core Products
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday its revenue rose 20.4% last year to $1.42 billion, thanks to big increases from its two core products,…
6160.HK
Structure Therapeutics Hopes to Wow Investors With Cutting-Edge Drug Tech
The maker of G-protein-coupled receptor (GPCR) drugs will raise more than $100 million in its IPO this week, making it the first major U.S. listing by a Chinese company this…
Losses Mount at InnoCare but Cash Cushion Dulls the Pain
The cancer drug developer logged another loss in the latest quarter but a cash pile of more than 9.2 billion yuan can sustain its business for the next five yearsKey…
Surging Beigene Catches Case of Forex Flu
The drug maker’s net loss grew in the third quarter due to weakness in the Chinese yuan, even as its revenue nearly doubledKey Takeaways:Surging sales for its two self-developed drugs…
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
The innovative drug maker has been approved to sell two more cancer drugs in China, but that hasn’t lifted its stock price Key Takeaways: Innovent Bio has brought several drugs…
